Compare SCSC & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCSC | CDNA |
|---|---|---|
| Founded | 1992 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 892.3M | 712.2M |
| IPO Year | 1994 | 2014 |
| Metric | SCSC | CDNA |
|---|---|---|
| Price | $41.85 | $20.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $43.00 | $26.00 |
| AVG Volume (30 Days) | 156.6K | ★ 816.3K |
| Earning Date | 01-29-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.79 | N/A |
| EPS | ★ 3.20 | 1.22 |
| Revenue | ★ $3,004,880,000.00 | $357,998,000.00 |
| Revenue This Year | $5.96 | $14.11 |
| Revenue Next Year | $5.06 | $12.00 |
| P/E Ratio | ★ $13.11 | $16.92 |
| Revenue Growth | N/A | ★ 14.46 |
| 52 Week Low | $28.75 | $10.96 |
| 52 Week High | $53.90 | $25.95 |
| Indicator | SCSC | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 54.34 | 71.98 |
| Support Level | $40.06 | $18.36 |
| Resistance Level | $42.24 | $19.95 |
| Average True Range (ATR) | 1.12 | 0.86 |
| MACD | 0.24 | 0.19 |
| Stochastic Oscillator | 65.12 | 99.42 |
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Modern Communications and Cloud. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.